MIN-102 Emerging Drug Insight and Market Forecast - 2032

“MIN-102 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about MIN-102 for Adrenoleukodystrophy in the 7MM. A detailed picture of the MIN-102 for Adrenoleukodystrophy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the MIN-102 for Adrenoleukodystrophy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MIN-102 market forecast, analysis for Adrenoleukodystrophy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Adrenoleukodystrophy.

Drug Summary

Leriglitazone (MIN-102) is under development by Minoryx Therapeutics. It is a novel, orally bioavailable, and selective PPAR gamma agonist with a superior profile for CNS-related diseases. It is a metabolite of pioglitazone, which shows an excellent brain penetration and safety profile, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. In X-ALD, mutations on ABCD1 trigger a cascade of events leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination, and axonal degeneration.

MIN-102, through its PPAR gamma activity, prevents such dysfunctions; thus, it has the potential to treat both AMN and CALD. It also reduces monocyte adhesion to the endothelial cells of the blood-brain barrier (BBB). This mechanism leads to BBB disruption and has a prominent role in the initiation of the CALD phenotype. The mechanism of action of leriglitazone in X-ALD was published in the Science Translational Medicine Journal.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MIN-102 description, mechanism of action, dosage and administration, research and development activities in Adrenoleukodystrophy.
• Elaborated details on MIN-102 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MIN-102 research and development activity in Adrenoleukodystrophy details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MIN-102.
• The report contains forecasted sales of MIN-102 for Adrenoleukodystrophy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Adrenoleukodystrophy.
• The report also features the SWOT analysis with analyst views for MIN-102 in Adrenoleukodystrophy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MIN-102 Analytical Perspective

In-depth MIN-102 Market Assessment

This report provides a detailed market assessment of MIN-102 in Adrenoleukodystrophy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

MIN-102 Clinical Assessment

The report provides the clinical trials information of MIN-102 for Adrenoleukodystrophy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Adrenoleukodystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MIN-102 dominance.
• Other emerging products for Adrenoleukodystrophy are expected to give tough market competition to MIN-102 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MIN-102 in Adrenoleukodystrophy.
• This in-depth analysis of the forecasted sales data of MIN-102 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MIN-102 in Adrenoleukodystrophy.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of MIN-102?
• What is the clinical trial status of the study related to MIN-102 in Adrenoleukodystrophy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MIN-102 development?
• What are the key designations that have been granted to MIN-102 for Adrenoleukodystrophy?
• What is the forecasted market scenario of MIN-102 for Adrenoleukodystrophy?
• What are the forecasted sales of MIN-102 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Adrenoleukodystrophy and how are they giving competition to MIN-102 for Adrenoleukodystrophy?
• Which are the late-stage emerging therapies under development for the treatment of Adrenoleukodystrophy?

This product will be delivered within 2 business days.